Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-24T12:18:03.975Z Has data issue: false hasContentIssue false
  • English
  • Français

Combinación de amisulprida y olanzapina en psicosis esquizofrénicas resistentes al tratamiento

Published online by Cambridge University Press:  12 May 2020

M. Zink ,
A. Henn  and
J. Thome
M. Zink
Affiliation:
Clínica de Psiquiatría y Psicoterapia, Instituto Central de Salud Mental, P. O. Box 12 21 20, 68072Mannheim, Alemania
A. Henn
Affiliation:
Clínica de Psiquiatría y Psicoterapia, Instituto Central de Salud Mental, P. O. Box 12 21 20, 68072Mannheim, Alemania
J. Thome
Affiliation:
Clínica de Psiquiatría y Psicoterapia, Instituto Central de Salud Mental, P. O. Box 12 21 20, 68072Mannheim, Alemania
Get access

Resumen

La esquizofrenia resistente al tratamiento lleva a menudo a la aplicación combinada de medicamentos antipsicóticos. Informamos de la primera experiencia con la combinación de olanzapina y amisulprida. Se pudo lograr mejoría del estado psicopatológico y los efectos secundarios, y las dosis de fármacos fueron más bajas que en monoterapia. Así, concluimos que este enfoque representa una opción terapéutica útil.

Keywords

EsquizofreniaMedicamentos antipsicóticosAmisulpridaOlanzapina
Type
Comunicación breve
Information
European Psychiatry (Ed. Española) , Volume 11 , Issue 3 , April 2004 , pp. 186 - 188
Copyright
Copyright © European Psychiatric Association 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Caccia, S.Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000;38(5):39–414.CrossRefGoogle ScholarPubMed
Conley, R.R., Meltzer, H.Y.Adverse events relatad to olanzapine. J Clin Psychiatry 2000;61(Suppl 8):26–9 [discussion 30].Google ScholarPubMed
Freudenreich, O., Goff, D.C.Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323–30.CrossRefGoogle ScholarPubMed
Hellewell, J.S.Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 1999;60 (Suppl 23): 1–9.Google ScholarPubMed
Koshino, Y.Algorithm for treatment-refractory schizophrenia. Psychiatry Clin Neurosci 1999;53(Suppl):S9–S13.Google ScholarPubMed
Lecrubier, Y., Azorin, M., Bottai, T., Dalery, J., Garrean, G., Lemperiere, T., et al. Consensus on the practical use o f amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology 2001;44(1):41–6.CrossRefGoogle Scholar
Leucht, S., Pitschel-Walz, G., Engel, R.R., Kissling, W.Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled triais. Am J Psychiatry 2002;159:180–90.CrossRefGoogle Scholar
Ring, B.J., Binkley, S.N., Vandenbranden, M., Wrighton, S.A.In vitre interaction of the antipsychotic agent olanzapine with human cytochromes p450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996;41(3):181–6.CrossRefGoogle Scholar
Stephenson, C.M., Pilowsky, L.S.Psychopharmacology of olanzapine. A review. Br J Psychiatry 1999;38(Suppl):52–8.CrossRefGoogle Scholar